Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,611 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Not applicable Interventional Results available

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression

NCT04366258
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Photobiomodulator, Sham
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Charlestown, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 2 Interventional

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

NCT00057239
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Radafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 4 Interventional

Electroencephalography (EEG) Biomarkers of Response in Depression

NCT00759122
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
venlafaxine (Effexor), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 21, 2026, 10:32 PM EDT
Completed No phase listed Observational

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

NCT00360256
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Not applicable Interventional

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

NCT02421965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT03002077
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
128
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

NCT00683852
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole 5mg, Aripiprazole 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial

NCT02646449
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 21, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension for GLYX13-C-202, NCT01684163

NCT02192099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Rapastinel (225 mg/450 mg IV administration)
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 21, 2026, 10:32 PM EDT
Not listed No phase listed Observational

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

NCT02724735
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NSI-189
Drug
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years to 61 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 21, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048
View directory record Official record
Conditions
Refractory Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 10:32 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

NCT06788249
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine only
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:32 PM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 4 Interventional

Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse

NCT00223197
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Substance Abuse
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 21, 2026, 10:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sleep TMS for Depression

NCT06824415
View directory record Official record
Conditions
Major Depression, Sleep
Interventions
TMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 10:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

NCT02253225
View directory record Official record
Conditions
Bipolar Disorder, Major Depression, Rumination
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

NCT00369343
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 21, 2026, 10:32 PM EDT
Not listed Not applicable Interventional

Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression

NCT01473615
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Chronic Pain
Interventions
Mindfulness Based Cognitive Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 21, 2026, 10:32 PM EDT
Completed No phase listed Observational

Neurocardiac Control in Major Depression

NCT00084162
View directory record Official record
Conditions
Depression, Involutional
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Neuroscience of Guided Learning in Depression

NCT03203954
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Standard Learning, Guided Learning: Instructed statistics, Guided Learning: Changing statistics
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 21, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

NCT01944969
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Not applicable Interventional

Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback

NCT06050070
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FMRI with sham controlled feedback, FMRI with real time feedback
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 10:32 PM EDT